Royalty Pharma plc EBIT

The latest EBIT for RPRX is $1.6B as of June 2026. That compares with $1.8B in the prior-year period — down 7.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Royalty Pharma plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, RPRX's EBIT moved from $1.8B to $1.6B — a 7.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Royalty Pharma plc's operating scale or balance-sheet position.

Against Healthcare companies, RPRX currently prints $1.6B for EBIT, while the sector average sits near $110B. That is roughly 98.5% below the sector mean. Large gaps often invite a closer look at Royalty Pharma plc's growth, margins, and balance sheet.

A EBIT figure of $1.6B for RPRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RPRX's EBIT ($1.6B), review year-over-year change from $1.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.